Application
Lane 1: Rat Brain Tissue Lysate Lane 2: Rat Brain Tissue Lysate Lane 3: MCF-7 Cell Lysate Lane 4: HELA Cell Lysate Lane 5: SMMC Cell Lysate Lane 6: CEM Cell LysateApplication
IHC-P of human mammary cancer tissue| Product Name | Presenilin 2 antibody |
|---|---|
| Antibody Type | Primary Antibodies |
| Product description | Rabbit Polyclonal antibody to Presenilin-2Alzheimer's disease (AD) patients with an inherited form of the disease carry mutations in the presenilin proteins (PSEN1 or PSEN2) or the amyloid precursor protein (APP). These disease-linked mutations result in increased production of the longer form of amyloid-beta (main component of amyloid deposits found in AD brains). Presenilins are postulated to regulate APP processing through their effects on gamma-secretase, an enzyme that cleaves APP. Also, it is thought that the presenilins are involved in the cleavage of the Notch receptor such that, they either directly regulate gamma-secretase activity, or themselves act are protease enzymes. Two alternatively spliced transcript variants encoding different isoforms of PSEN2 have been identified. [provided by RefSeq, Jul 2008] |
| Immunogen | A synthetic peptide corresponding to a sequence at the N-terminal of human Presenilin-2, different from the related mouse and rat sequences by two amino acids. |
| Clonality | Polyclonal |
|---|---|
| Isotype | IgG |
| Host Species | Rabbit |
| Tested Applications | IHC-FIHC-PWB |
| IHC-F:1:20~1:50 IHC-P:1:20~1:100 WB:1:250~1:1000 Notes:Optimal dilutions/concentrations should be determined by the researcher. |
|
| Species Reactivity | HumanMouseRat |
| Concentration | 0.5mg/ml |
| Purification | Affinity purified |
| Gene Synonyms | presenilin 2 (Alzheimer disease 4) CMD1V AD3L STM2 PSEN2 PS2 AD4 |
|---|---|
| Target | Presenilin-2 |
Application
Lane 1: Rat Brain Tissue Lysate Lane 2: Rat Brain Tissue Lysate Lane 3: MCF-7 Cell Lysate Lane 4: HELA Cell Lysate Lane 5: SMMC Cell Lysate Lane 6: CEM Cell Lysate
Application
IHC-P of human mammary cancer tissue| Application Notes | IHC-F:1:20~1:50 IHC-P:1:20~1:100 WB:1:250~1:1000 Notes:Optimal dilutions/concentrations should be determined by the researcher. |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | Keep as concentrated solution. Aliquot and store at -20ºC. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | 5% BSA, 0.9% NaCl, 0.2% Na2HPO4, 0.05% Thimerosal, 0.05% NaN3. |
